Status: Not yet recruiting
Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)
Participants needed: 36
Trial details
Age: 18-75Biological sex: AllType: ObservationalSponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityUpdated: Oct 12, 2023
Eligibility criteria
Inoperable stage IIIB-IV patients with non-small cell lung cancer; [+5]
The patient is currently receiving other anticoagulant therapy; [+4]